First Light Diagnostics is one of the biggest names in developing products for the detection of life-threatening conditions. The products usually function in a quick manner and are cost-effective. Recently, the company has announced its participation in the global initiative of the Antimicrobial Resistance Challenge (AMR) with the Centre for Disease Control and Prevention.
The main purpose of the challenge is to combat the rising levels of antibacterial resistance worldwide. To do so, each one of the participating organizations and companies will help in the elimination of any unnecessary use of antimicrobial products in daily life.
Originally launched in the United Nations General Assembly in 2018, the project has been joined by over 300 companies, non-profit and non-governmental organizations worldwide. The fight is also expected to be joined by even more similar companies from different countries in the incoming years.
Currently, antimicrobial resistance is one of the biggest threats to public health around the globe. Research has identified species of microbes that are resistant to even the most advanced forms of drugs.
Consequently, many of the hospitals are filled with cases of people suffering from potentially fatal antimicrobial-resistant infections. Secondly, a comeback of the deadliest diseases from the past with resistant pathogens is also a big possibility. Therefore, a joined initiative is one of the primary steps needed at the time.
There is not only the need for cutting down the use of antibiotics in each of the countries but also finding the most effective therapies and alternative treatments in cases of suspected antibiotic resistance.
First Light Diagnostics, which already provides tools to control antimicrobial-resistant infections, has committed to creating a platform that will provide health professionals with targeted antibiotics in patients with a threat of resistant infections.
Additionally, the data reporting and testing procedures will be made easier by a user-friendly online database so that any doctor or clinician involved in the treatment of a resistant infection can directly access results and information on the patient.
The CEO of First Light Diagnostics, David Macdonald, says that the company is not only honored to part of the global fight against antimicrobial resistance but will also provide as much help as needed.
With the products by First Light Diagnostics, clinicians will be able to check for antibiotic susceptibility and effectively treat a person who is at the initial stages or on the onset of antimicrobial resistance.
For instance, the MultiPath technology by the company is an easy-to-use test that can identify the pathogen causing the infection within thirty minutes and only a few hours in showing whether the person is at a threat of antibiotic resistance.
Hence, the primary patient samples can be used without a culture step in detection which often takes too long to show results. Skipping the culture step means that there will also be a decreased prescription and use of broad-spectrum antibiotics.
The MultiPath system have now begun to become a part of major clinical trials based on studying antimicrobial resistance. By the year 2020, the devices will also have approval from the Food and Drug Authority. (FDA).